Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market Size, Product Pipelines, Clinical Trials, Latest Developments, Demand and Growth Forecast 

What is Driving Growth in the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market? 

The Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market is undergoing a significant transformation, propelled by increasing demand for biologics targeting inflammatory and autoimmune diseases. These inhibitors, particularly used in the treatment of conditions like psoriasis, psoriatic arthritis, and Crohn’s disease, are gaining prominence due to their superior efficacy and targeted immunomodulatory actions. The global sales of IL-12/IL-23 inhibitors exceeded $6.5 billion in 2024, showcasing their growing footprint in the immunotherapy segment. The expanding therapeutic landscape has elevated the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market from a niche segment to a high-impact global industry. 

What are the Demand Catalysts in the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market? 

Rising demand in the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market is being shaped by increasing prevalence of chronic autoimmune diseases. For instance, psoriasis affects over 125 million individuals globally, with nearly 30% of those cases advancing to psoriatic arthritis, intensifying the need for long-term, high-efficacy treatment options. Biologics targeting IL-12 and IL-23 pathways have shown clinical response rates of over 70% in plaque psoriasis, with significant patient adherence observed due to lower dosing frequency compared to traditional therapies. Consequently, the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market is expected to experience a compound annual growth rate (CAGR) of over 9.2% from 2025 to 2030. 

What Trends Are Reshaping the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market? 

Emerging innovation trends are redefining the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market. For example, pipeline drugs with dual-target mechanisms, which simultaneously inhibit both interleukins and downstream signaling molecules, are gaining momentum. Such advancements offer higher selectivity and longer-lasting disease control. Additionally, biosimilar development is intensifying, particularly in Asia-Pacific markets, where biologics pricing pressures have opened up opportunities for cost-effective alternatives. The increasing entry of biosimilars is anticipated to expand accessibility, contributing to Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market penetration across developing economies. 

What is the Role of Technological Advancements in the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market? 

Technological innovation is proving to be a key catalyst in the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market. Advanced monoclonal antibody engineering has resulted in enhanced specificity and longer half-lives. For instance, newer drugs like risankizumab offer a dosing schedule of once every 12 weeks after initial loading, thereby reducing patient burden and improving compliance. Such innovations have directly contributed to a 27% increase in new prescriptions over the last two years. Furthermore, digital platforms supporting remote biologics monitoring and adherence tracking are enabling healthcare providers to optimize treatment outcomes, reinforcing sustained growth in the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market. 

How is Patient Preference Shaping the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market? 

Patient-centric factors are playing an increasingly pivotal role in the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market. Preference for self-administered therapies has surged, as patients seek convenience without compromising efficacy. For instance, nearly 68% of biologic-using patients in North America prefer subcutaneous injection formats over intravenous infusions. This demand has catalyzed the development of auto-injectors and at-home administration kits, which has directly increased market uptake. By 2025, subcutaneous biologics are expected to command over 60% share of the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market. 

What Geographic Markets are Leading Growth in the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market? 

Geographically, the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market is seeing robust expansion in North America and Western Europe due to early biologics adoption, strong reimbursement frameworks, and high disease awareness. North America accounted for over 42% of global revenue in 2024. However, Asia-Pacific is emerging as the fastest-growing region, with countries like China and India exhibiting annual growth rates exceeding 13%, driven by rising biologics approvals and public healthcare investments. The Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market is witnessing increased clinical trial activity in this region, further accelerating market maturity. 

What Role Do Strategic Collaborations Play in the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market? 

Strategic alliances are reshaping the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market. Collaborations between pharmaceutical giants and biotech startups have enabled co-development of next-generation inhibitors. For instance, co-commercialization agreements have allowed for faster regional market penetration, particularly in Europe and Latin America. Moreover, licensing deals focused on biosimilars and novel biologics have surged by over 40% in the last three years, reflecting a strategic shift towards diversification of portfolios. These partnerships are expected to add over $2.1 billion in value to the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market by 2028. 

What Regulatory Factors Influence the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market? 

Regulatory evolution continues to influence the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market. Recent acceleration of biologic approvals through expedited review pathways has reduced time-to-market for promising candidates. For instance, the average biologic approval timeline in the U.S. has reduced from 12 months to under 9 months for therapies demonstrating breakthrough potential. Similarly, harmonization of biosimilar approval standards across the EU and Asia-Pacific has enhanced market predictability. As regulatory barriers lower, the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market Size is expected to exceed $10.7 billion by the end of 2027. 

How Are Pricing and Reimbursement Trends Impacting the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market? 

Pricing dynamics are exerting a considerable influence on the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market. While branded biologics continue to command premium pricing—averaging $55,000 annually per patient—the growing entry of biosimilars is introducing pricing corrections. In countries with strong price controls, such as Japan and Brazil, biosimilars are priced 30–45% lower than originator products, leading to broader adoption in public health systems. Reimbursement expansion through government health schemes is expected to add over 18 million eligible patients globally to the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market by 2030. 

What is the Forecast for the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market Size? 

The Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market Size is poised for exponential growth, with projections indicating a rise from $6.5 billion in 2024 to over $11.2 billion by 2030. This forecast is anchored by expanding clinical indications, deepening patient access, and accelerating biologic innovation. For instance, ongoing clinical studies are exploring IL-12/23 inhibitors for new autoimmune targets like hidradenitis suppurativa and lupus, which could add over $1.5 billion in annual revenue potential. As therapeutic applications diversify, the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market Size will continue to reflect broader clinical and commercial value. 

What Competitive Dynamics are Redefining the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market? 

Competition in the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market is intensifying, with top players continuously innovating to retain market share. Major pharmaceutical firms are investing heavily in lifecycle management strategies such as label expansions and fixed-dose combinations. For instance, some developers are targeting combination biologics that inhibit IL-12/23 alongside IL-17, which could deliver synergistic effects in patients with refractory conditions. Meanwhile, emerging players are pursuing niche indications and regional markets, contributing to a more fragmented and dynamic competitive landscape within the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market. 

“Track Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Sales and Demand through our Database”

• • • Interleukin-12 & 23 (IL-12/IL-23) Inhibitors sales database for 10+ countries worldwide
    • Country-wise demand and growth forecast, latest investments in Interleukin-12 & 23 (IL-12/IL-23) Inhibitors
    • Interleukin-12 & 23 (IL-12/IL-23) Inhibitors clinical trials database
    • Interleukin-12 & 23 (IL-12/IL-23) Inhibitors product pipeline database

What Geographies Are Accelerating the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market? 

The Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market is experiencing highly asymmetrical growth across global regions. North America continues to dominate, driven by mature biologics infrastructure, patient awareness, and expansive insurance coverage. In 2024, North America held over 42% of the total market share, with the U.S. accounting for more than $3.2 billion in annual revenue. For example, over 7.5 million people in the U.S. are diagnosed with psoriasis, of which a significant portion is now treated with targeted IL-12/23 biologics. 

In contrast, the Asia-Pacific region is demonstrating the highest growth velocity. The Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market in Asia-Pacific is expanding at a CAGR of 13.7%, powered by rapid biologics approvals, increased physician education, and government-driven healthcare modernization. Countries like China and India are experiencing a surge in Interleukin-12 & 23 (IL-12/IL-23) Inhibitors demand, with over 18% annual growth in prescriptions due to rising diagnosis rates of inflammatory diseases and a shift toward targeted therapies. 

Western Europe remains a key contributor to the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market, with Germany, France, and the UK making up over 70% of the region’s revenue. Demand in this region is closely tied to national reimbursement policies and formulary listings. In Germany, for instance, IL-12/23 biologics now account for more than 45% of all biologic prescriptions in dermatology. 

How is the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market Segmented by Indication? 

Segment-wise, the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market is currently led by plaque psoriasis, which contributes approximately 55% of total market revenue. For instance, therapies such as guselkumab and tildrakizumab have achieved market penetration rates of over 30% within the psoriasis segment due to their high PASI (Psoriasis Area and Severity Index) response scores. 

Psoriatic arthritis holds the second-largest share in the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market, with increasing adoption of dual-action inhibitors showing effectiveness in managing joint and skin symptoms simultaneously. This segment is growing at a CAGR of 8.5%, driven by the increasing diagnosis rate, which has risen by 11% globally in the past three years. 

Crohn’s disease is another emerging indication in the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market. The chronic nature of the disease and the failure of conventional immunosuppressants in many patients has led to a 25% increase in the use of biologics, especially among patients with moderate to severe disease. 

What Role Does Product Pipeline Play in the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market? 

A robust product development pipeline is one of the defining features of the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market. Currently, more than 22 novel compounds targeting IL-12, IL-23, or both are in various stages of clinical development. For instance, newer biologics like mirikizumab and brazikumab are under late-stage evaluation and are expected to offer greater specificity and reduced immunogenicity. 

Datavagyanik notes that nearly 60% of the current pipeline is focused on extending applications into rarer autoimmune diseases such as uveitis and hidradenitis suppurativa. The entry of such products is expected to expand the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors demand across previously untapped therapeutic domains, adding over $1.1 billion in addressable revenue by 2029. 

Moreover, the shift from intravenous to subcutaneous delivery formats is heavily reflected in pipeline products, which aim to enhance convenience and patient adherence. Over 75% of drugs in development are now focused on long-acting subcutaneous formulations, which aligns with emerging trends in patient preference. 

How Are Clinical Trials Fueling Growth in the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market? 

The Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market is heavily shaped by clinical trials validating the safety and efficacy of these agents across multiple disease settings. As of mid-2025, more than 120 clinical trials focusing on IL-12/23 pathway inhibitors are ongoing globally. These trials are not limited to dermatology and gastroenterology but are extending into pulmonary and neurological domains as well. 

For example, a Phase III trial testing an IL-12/23 inhibitor for ulcerative colitis demonstrated clinical remission in 52% of patients compared to 21% in the placebo group. Similarly, exploratory trials in conditions like multiple sclerosis and Behçet’s disease are generating encouraging immunological data, suggesting broader future applicability of these agents. 

Clinical trial density is highest in North America and Western Europe, with more than 65% of trials concentrated in these regions due to advanced clinical infrastructure and patient recruitment efficiency. However, Asia-Pacific is emerging as a strategic region for Phase II development, accounting for over 18% of all new trial initiations in 2024. 

What Investment Trends Are Powering the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market? 

Investment in the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market is scaling rapidly, with over $4.8 billion in R&D funding allocated to this drug class over the past three years. Large pharmaceutical companies are intensifying their focus on expanding IL-12/23 portfolios due to strong commercial returns. For example, the return on investment (ROI) for leading IL-12/23 inhibitors has exceeded 22% annually, prompting capital reallocation from traditional immunosuppressants to advanced biologics. 

Private equity and venture capital interest in companies developing IL-12/23 inhibitors has also surged. In 2024 alone, over $900 million was invested into early-stage startups working on next-generation biologics and biosimilars in this space. These investments are targeted toward platform technologies enabling higher affinity antibodies and modular manufacturing, which can shorten development timelines by 20–25%. 

Mergers and acquisitions have further shaped the competitive landscape of the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market. Several deals valued at over $1 billion each have been executed in the past 18 months, with acquiring companies targeting late-stage pipeline assets and regional distribution rights to fast-track market entry. 

What Patterns of Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Demand Are Emerging Globally? 

The Interleukin-12 & 23 (IL-12/IL-23) Inhibitors demand is moving from specialist-only settings to broader, community-based care environments. In the U.S., primary care physicians now account for 12% of all new biologic initiations, reflecting wider clinical adoption. In emerging economies, government-backed awareness programs are driving Interleukin-12 & 23 (IL-12/IL-23) Inhibitors demand, especially in urban areas with increasing autoimmune disease diagnosis rates. 

Datavagyanik forecasts a 3.2x increase in Interleukin-12 & 23 (IL-12/IL-23) Inhibitors demand in tier-2 cities of India and Southeast Asia between 2025 and 2030, aided by falling biosimilar prices and physician education programs. These trends indicate a strategic shift in market dynamics, with demand becoming more decentralized and democratized. 

How Are Subpopulations and Personalized Therapy Impacting the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market? 

Personalized medicine is increasingly influencing the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market. Advances in biomarker diagnostics now enable patient stratification based on IL-12/23 expression profiles, improving therapeutic precision. For instance, patients with high IL-23p19 expression demonstrate significantly better response rates to selective inhibitors, with clinical efficacy reaching up to 80% clearance at week 16 in some trials. 

These insights are leading to the design of precision dosing algorithms and companion diagnostics, expected to elevate both outcomes and cost-efficiency. As these personalized strategies scale, they are forecast to increase Interleukin-12 & 23 (IL-12/IL-23) Inhibitors demand within specialty care networks by over 40% through 2030. 

 

“Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Clinical Trials and Product Pipeline Database”

• • • Interleukin-12 & 23 (IL-12/IL-23) Inhibitors top companies market share for leading players
    • Interleukin-12 & 23 (IL-12/IL-23) Inhibitors clinical trials database
    • Interleukin-12 & 23 (IL-12/IL-23) Inhibitors product pipeline database

Who are the Leading Companies in the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market? 

The Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market is led by a concentrated group of pharmaceutical companies that dominate both the commercial and developmental landscape. Collectively, these players control approximately 70 percent of the global market, underscoring the strategic value of IL-12/IL-23 biologics in autoimmune disease management. 

Janssen Pharmaceuticals holds the top position, with guselkumab (marketed as Tremfya) contributing over 22 percent to global market share. This therapy is widely prescribed for moderate to severe plaque psoriasis and psoriatic arthritis, supported by a convenient dosing schedule and robust clinical response. 

AbbVie is another major player in the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market, with its IL-23p19 inhibitor risankizumab (Skyrizi). With an estimated 18 percent market share, risankizumab has demonstrated strong uptake across dermatology and gastroenterology applications, particularly in Crohn’s disease where it received expanded approval. 

Merck & Co. maintains a strong position with ustekinumab (Stelara), a dual inhibitor of IL-12 and IL-23. Stelara contributes approximately 16 percent of the total market, and its multi-indication approval for psoriasis, psoriatic arthritis, and Crohn’s disease continues to support growth. 

Sun Pharma also plays a significant role with tildrakizumab (marketed as Ilumya and Kyntheum), holding roughly 7 percent of the market. The product has seen particularly strong adoption in dermatology practices across Europe and select Asian markets. 

Additional players like Boehringer Ingelheim and Eli Lilly are advancing late-stage assets such as mirikizumab, targeting inflammatory bowel diseases, and these assets are expected to capture incremental share over the next few years. Together, emerging players and biosimilar developers constitute nearly 28 percent of the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market. 

 

Which Products Are Shaping the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market? 

Key product-level differentiation has played a vital role in shaping the competitive structure of the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market. 

Guselkumab offers quarterly dosing following the initial loading phase and is known for achieving high skin clearance rates, with many patients reaching PASI-90 benchmarks by week 16. This product is widely preferred in plaque psoriasis management and is being studied for broader applications. 

Risankizumab has gained strong momentum due to its effectiveness in both dermatological and gastrointestinal indications. The approval for Crohn’s disease in several major markets has added significant volume to AbbVie’s market share, with additional label expansion strategies underway. 

Stelara remains unique as a dual-action inhibitor targeting both IL-12 and IL-23. Its broad spectrum of indication coverage across multiple immune-mediated inflammatory diseases allows it to retain a substantial patient base despite competition from more selective agents. 

Tildrakizumab has found niche positioning due to its favorable safety profile and cost-effective pricing in publicly funded health systems. Its twice-yearly maintenance dosing further supports adherence among long-term users. 

Mirikizumab, currently under regulatory review, is expected to be a strong contender in the ulcerative colitis market, with high clinical remission rates observed in late-stage trials. Its dual applicability in gastrointestinal and dermatological segments enhances its commercial viability. 

 

What is the Competitive Market Share Structure? 

The Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market shows a competitive yet consolidated structure: 

• Janssen (Tremfya): 22 percent 

• AbbVie (Skyrizi): 18 percent 

• Merck & Co. (Stelara): 16 percent 

• Sun Pharma (Ilumya/Kyntheum): 7 percent 

• Boehringer Ingelheim (Mirikizumab): 5 percent 

• Eli Lilly (Mirikizumab pipeline): 4 percent 

• Others and emerging players: 28 percent 

This distribution reflects strong brand loyalty, differentiated indications, and ongoing lifecycle management strategies from top-tier companies. 

 

What Recent Developments Are Reshaping the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market? 

Recent months have witnessed a surge in activity within the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market. In early 2025, AbbVie received approval for risankizumab in additional Crohn’s disease settings, adding several hundred million dollars in projected revenue. This extension also triggered broader formulary inclusion across private insurers and public health schemes in North America and Europe. 

Janssen expanded guselkumab into pediatric psoriasis, increasing the addressable patient pool by an estimated 12 to 15 percent in high-income countries. The company also announced its intention to initiate clinical trials in hidradenitis suppurativa, a niche but underserved inflammatory skin condition. 

Sun Pharma filed for approval of tildrakizumab in Japan, with expected market entry by Q4 2025. The company aims to strengthen its presence in Asia-Pacific, where Interleukin-12 & 23 (IL-12/IL-23) Inhibitors demand is expanding rapidly due to rising diagnosis and biologic adoption rates. 

Mirikizumab continues to attract strategic investments. A major licensing agreement between Eli Lilly and Boehringer Ingelheim was signed in 2025, covering co-commercialization rights in North America and Europe. The collaboration is designed to accelerate development in ulcerative colitis and expand into Crohn’s disease and other immune-mediated indications. 

 

What’s in the Pipeline and What’s Next? 

The product pipeline in the Interleukin-12 & 23 (IL-12/IL-23) Inhibitors Market is rich with innovation. Over 20 assets are currently under development globally. Late-stage candidates such as brazikumab are targeting high-unmet-need populations, with promising interim data showing clinical remission in nearly 44 percent of Crohn’s patients by week 12. 

Several biosimilars to ustekinumab and tildrakizumab are in preclinical and Phase I stages, indicating growing interest in cost-competitive options. These biosimilars are expected to enter the market post-patent expiration around 2026 to 2027, intensifying competitive pressures and broadening access in cost-sensitive regions. 

Multiple trials are now exploring combination therapies, integrating IL-12/23 inhibitors with JAK inhibitors or IL-17 blockers, aimed at patients with refractory or overlapping autoimmune conditions. Such studies represent the next phase of market evolution toward combination biologics and personalized medicine. 

Investments in manufacturing infrastructure are also scaling. Major firms have announced expansions of biologics facilities in Europe and Asia, signaling preparation for anticipated demand growth over the next five years.